Display options
Cite
D'Auria F, Centurione L, Centurione MA, et al. Regulation of Cancer Cell Responsiveness to Ionizing Radiation Treatment by Cyclic AMP Response Element Binding Nuclear Transcription Factor. Front Oncol. 2017;7:76doi: 10.3389/fonc.2017.00076.
D'Auria, F., Centurione, L., Centurione, M. A., Angelini, A., & Di Pietro, R. (2017). Regulation of Cancer Cell Responsiveness to Ionizing Radiation Treatment by Cyclic AMP Response Element Binding Nuclear Transcription Factor. Frontiers in oncology, 776. https://doi.org/10.3389/fonc.2017.00076
D'Auria, Francesca, et al. "Regulation of Cancer Cell Responsiveness to Ionizing Radiation Treatment by Cyclic AMP Response Element Binding Nuclear Transcription Factor." Frontiers in oncology vol. 7 (2017): 76. doi: https://doi.org/10.3389/fonc.2017.00076
D'Auria F, Centurione L, Centurione MA, Angelini A, Di Pietro R. Regulation of Cancer Cell Responsiveness to Ionizing Radiation Treatment by Cyclic AMP Response Element Binding Nuclear Transcription Factor. Front Oncol. 2017 May 05;7:76. doi: 10.3389/fonc.2017.00076. eCollection 2017. PMID: 28529924; PMCID: PMC5418225.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2017 May 05;7:76. doi: 10.3389/fonc.2017.00076. eCollection 2017.

Regulation of Cancer Cell Responsiveness to Ionizing Radiation Treatment by Cyclic AMP Response Element Binding Nuclear Transcription Factor.

Frontiers in oncology

Francesca D'Auria, Lucia Centurione, Maria Antonietta Centurione, Antonio Angelini, Roberta Di Pietro

Affiliations

  1. Department of Cardiac and Vascular Surgery, Campus Bio-Medico University of Rome, Rome, Italy.
  2. Department of Medicine and Ageing Sciences, G. d'Annunzio University, Chieti, Italy.
  3. Institute of Molecular Genetics, National Research Council-Pavia, Chieti, Italy.
  4. Ageing Research Center, CeSI, G. d'Annunzio University Foundation, Chieti, Italy.

PMID: 28529924 PMCID: PMC5418225 DOI: 10.3389/fonc.2017.00076

Abstract

Cyclic AMP response element binding (CREB) protein is a member of the CREB/activating transcription factor (ATF) family of transcription factors that play an important role in the cell response to different environmental stimuli leading to proliferation, differentiation, apoptosis, and survival. A number of studies highlight the involvement of CREB in the resistance to ionizing radiation (IR) therapy, demonstrating a relationship between IR-induced CREB family members' activation and cell survival. Consistent with these observations, we have recently demonstrated that CREB and ATF-1 are expressed in leukemia cell lines and that low-dose radiation treatment can trigger CREB activation, leading to survival of erythro-leukemia cells (K562). On the other hand, a number of evidences highlight a proapoptotic role of CREB following IR treatment of cancer cells. Since the development of multiple mechanisms of resistance is one key problem of most malignancies, including those of hematological origin, it is highly desirable to identify biological markers of responsiveness/unresponsiveness useful to follow-up the individual response and to adjust anticancer treatments. Taking into account all these considerations, this mini-review will be focused on the involvement of CREB/ATF family members in response to IR therapy, to deepen our knowledge of this topic, and to pave the way to translation into a therapeutic context.

Keywords: DNA repair; cancer; cyclic AMP response element binding/activating transcription factor; ionizing radiation; nuclear transcription factors; radio-resistance; radio-sensitivity; radiotherapy

References

  1. Blood. 2002 Oct 1;100(7):2292-302 - PubMed
  2. Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):5898-903 - PubMed
  3. J Biol Chem. 1998 Aug 28;273(35):22841-7 - PubMed
  4. J Cell Biochem. 2007 Mar 1;100(4):1070-9 - PubMed
  5. Nat Rev Cancer. 2008 Jul;8(7):523-34 - PubMed
  6. Curr Pharm Des. 2010;16(12 ):1427-42 - PubMed
  7. Exp Hematol. 2012 Apr;40(4):295-306.e5 - PubMed
  8. Mol Cell Biol. 1996 Oct;16(10):5546-56 - PubMed
  9. J Neurosci Res. 2004 Nov 15;78(4):570-9 - PubMed
  10. Mutat Res. 2015 Dec;782:23-33 - PubMed
  11. J Biol Chem. 2004 Jun 18;279(25):26176-83 - PubMed
  12. Nature. 1993 Oct 28;365(6449):855-9 - PubMed
  13. Int J Oncol. 2016 Jan;48(1):28-36 - PubMed
  14. J Exp Med. 1996 Dec 1;184(6):2399-404 - PubMed
  15. Biol Bull. 2009 Oct;217(2):202-12 - PubMed
  16. Biochem J. 1999 Oct 1;343 Pt 1:249-55 - PubMed
  17. Neoplasma. 2006;53(6):518-23 - PubMed
  18. Am J Cancer Res. 2014 Nov 19;4(6):850-61 - PubMed
  19. Int J Immunopathol Pharmacol. 2009 Jul-Sep;22(3):679-88 - PubMed
  20. J Cell Biochem. 2002;86(3):553-60 - PubMed
  21. Int J Radiat Biol. 2008 Apr;84(4):315-24 - PubMed
  22. Epigenetics. 2010 Jan 1;5(1):9-15 - PubMed
  23. Int J Hematol. 2000 Jul;72(1):12-9 - PubMed
  24. J Radiat Res. 2004 Sep;45(3):357-72 - PubMed
  25. J Biol Chem. 2015 Apr 10;290(15):9604-13 - PubMed
  26. J Biol Chem. 1994 Jan 28;269(4):2349-52 - PubMed
  27. Pharmacol Ther. 2016 Apr;160:65-83 - PubMed
  28. Biochem Biophys Res Commun. 2016 Jan 15;469(3):363-9 - PubMed
  29. Cancer Res. 1999 Oct 15;59(20):5365-9 - PubMed
  30. Exp Mol Med. 2009 Aug 31;41(8):592-600 - PubMed
  31. Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11566-71 - PubMed
  32. Cell Signal. 2005 Feb;17 (2):253-62 - PubMed
  33. Oncogene. 2003 Sep 1;22(37):5813-27 - PubMed
  34. J Clin Oncol. 2006 Oct 1;24(28):4539-44 - PubMed
  35. J Radiat Res. 2006 Jun;47(2):113-20 - PubMed
  36. Cell Res. 2007 Apr;17(4):324-32 - PubMed
  37. J Biol Chem. 1998 Dec 4;273(49):32377-9 - PubMed
  38. EMBO J. 1995 Dec 15;14(24):6148-56 - PubMed
  39. Cancer Res. 2000 May 15;60(10):2576-8 - PubMed
  40. J Biol Chem. 2000 Apr 14;275(15):10761-6 - PubMed
  41. J Biol Chem. 2006 Jan 20;281(3):1692-7 - PubMed
  42. Nat Rev Mol Cell Biol. 2001 Aug;2(8):589-98 - PubMed
  43. Int J Radiat Biol. 1994 Apr;65(4):449-55 - PubMed
  44. Cancer Res. 1996 Sep 1;56(17):4006-12 - PubMed
  45. Mol Cell Biol. 1997 Sep;17 (9):5386-99 - PubMed
  46. Tumour Biol. 2016 Jun;37(6):7315-25 - PubMed
  47. Semin Radiat Oncol. 2009 Apr;19(2):96-105 - PubMed
  48. Cell Death Dis. 2013 Feb 14;4:e498 - PubMed
  49. Trends Biochem Sci. 1999 Jul;24(7):281-5 - PubMed
  50. Int J Mol Sci. 2013 Jul 31;14(8):15931-58 - PubMed
  51. Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6587-92 - PubMed
  52. Oncogene. 1997 Jun 12;14(23):2759-66 - PubMed
  53. Drug Resist Updat. 2001 Oct;4(5):303-13 - PubMed
  54. Nat Rev Cancer. 2007 Feb;7(2):118-29 - PubMed
  55. J Clin Gastroenterol. 1979 Mar;1(1):9-39 - PubMed
  56. Oncogene. 2004 Apr 12;23(16):2825-37 - PubMed
  57. J Neurochem. 1999 Nov;73(5):1836-42 - PubMed
  58. Eur J Biochem. 1997 Nov 15;250(1):7-18 - PubMed
  59. Cell Death Dis. 2013 Apr 25;4:e605 - PubMed
  60. J Cell Physiol. 2008 Jan;214(1):192-200 - PubMed
  61. Future Oncol. 2010 Oct;6(10):1563-76 - PubMed
  62. Oncogene. 2004 May 27;23(25):4362-70 - PubMed
  63. Curr Gastroenterol Rep. 2011 Oct;13(5):449-57 - PubMed
  64. Semin Oncol. 2008 Aug;35(4):418-29 - PubMed
  65. Int J Immunopathol Pharmacol. 2004 May-Aug;17(2):181-90 - PubMed
  66. Curr Opin Cell Biol. 2002 Dec;14(6):727-33 - PubMed
  67. Int J Mol Sci. 2016 Jan 14;17 (1):null - PubMed
  68. Circulation. 2004 Jun 22;109 (24):3042-9 - PubMed
  69. Am J Cancer Res. 2011;1(7):834-44 - PubMed
  70. Int J Radiat Biol. 1994 Feb;65(2):217-27 - PubMed
  71. Curr Protein Pept Sci. 2015;16(4):279-94 - PubMed
  72. Curr Cancer Drug Targets. 2010 Jun;10(4):384-91 - PubMed
  73. Apoptosis. 2003 Jan;8(1):19-27 - PubMed
  74. Int J Immunopathol Pharmacol. 2006 Jul-Sep;19(3):517-24 - PubMed
  75. Nature. 1995 Mar 2;374(6517):85-8 - PubMed
  76. Histochem Cell Biol. 2007 Mar;127(3):327-33 - PubMed
  77. Drug Discov Today. 2007 Oct;12(19-20):794-805 - PubMed
  78. Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3829-34 - PubMed

Publication Types